Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
(Separated Public Comment and Tech Conf into separate lines) |
|||
Line 85: | Line 85: | ||
| Technical Confirmation | | Technical Confirmation | ||
| 2017.09.15 | | 2017.09.15 | ||
− | + | | [[Media:QIBA PET Amyloid Profile changes.pdf| Profile changes for Technical Confirmation, 2022-04-15]] | |
− | |||
|- | |- | ||
|PET Amyloid 2017 | |PET Amyloid 2017 | ||
|Public Comment | |Public Comment | ||
|2017.09.15 | |2017.09.15 | ||
− | | | + | |[[Media:QIBA PET Amyloid Comments all resolved.xlsx| Public Comment Resolutions 2018-05-02]] |
− | | | ||
|- | |- | ||
| [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] | | [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] |
Revision as of 23:59, 13 June 2022
Comments received during Public Comment, Technical Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.